Posted by Michael Wonder on 01 Aug 2024
Prestige Biopharma's Herceptin biosimilar Tuznue receives positive CHMP opinion from the EMA
31 July 2024 - Following approval by the European Commission, Prestige Biopharma's Herceptin biosimilar Tuznue would become the first biosimilar from a Singaporean company to be authorised in the European Union.
Prestige Biopharma announced that the CHMP of the EMA has recommended marketing authorisation for Tuznue, a Herceptin (trastuzumab) biosimilar.
